Cargando…
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy represents the most advanced immunotherapy against relapsed/refractory B cell malignancies. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are distinctive, known CAR T-cell acute adverse events, he...
Autores principales: | Accorsi Buttini, Eugenia, Farina, Mirko, Lorenzi, Luisa, Polverelli, Nicola, Radici, Vera, Morello, Enrico, Colnaghi, Federica, Almici, Camillo, Ferrari, Emilio, Bianchetti, Andrea, Leoni, Alessandro, Re, Federica, Bosio, Katia, Bernardi, Simona, Malagola, Michele, Re, Alessandro, Russo, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897055/ https://www.ncbi.nlm.nih.gov/pubmed/36741006 http://dx.doi.org/10.3389/fonc.2023.1036455 |
Ejemplares similares
-
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
por: Accorsi Buttini, E., et al.
Publicado: (2022) -
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022) -
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection
por: Bernardi, Simona, et al.
Publicado: (2022) -
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia
por: Malagola, Michele, et al.
Publicado: (2023) -
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY
por: Bernardi, Simona, et al.
Publicado: (2023)